These properties make GDC a novel and ideal candidate for transiently inducing a leaky, infant-like epithelial phenotype, a previously unexplored approach for modeling early-life gut barrier function in vitro
Addressing volume loss, skin laxity, and cellulite issues early on allows patients to achieve meaningful results with minimally invasive treatments, potentially avoiding the necessity for surgical interventions
This adjustment phase can last for a few weeks, and headaches may subside as the body adapts to the medication
Possible side effects may include temporary redness, irritation, injection-site discomfort, or rare allergic reactions
Originally developed for type 2 diabetes and weight management, the GLP-1/GIP medication tirzepatide under the brand name Zepbound is now FDA-approved to treat obstructive sleep apnea